Acute Kidney InjuryNCT06898944
Prognosis and Risk Factors for Acute Kidney Injury
An observational study of Acute Kidney Injury, run by Seoul National University Hospital at 1 site in South Korea.
Trial summary
The aim of our study is to analyze the accurate diagnosis and prognosis of acute kidney injury (AKI) based on its severity and to define long-term clinical and socioeconomic outcomes. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Acute Kidney Injury
- How many people
- 320,000 participants
- Where
- 1 siteSouth Korea
- Study dates
- 22 Aug 2022to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults (≥20 years old) who visited Parcitipating Medical Center (Seoul National University Hospital, Bundang Seoul National University Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center) between 2006 and 2021
Who may be able to join
- Adults over 20 years old who visited Parcitipating Medical Center (Seoul National University Hospital, Bundang Seoul National University Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center) between 2006 and 2021
- The AKI group is defined as individuals meeting the AKI diagnostic criteria of the KDIGO Guideline (an increase in serum creatinine of ≥0.3 mg/dL or ≥1.5 times the baseline level) is enrolled.
- The Control Group is defined as individuals from the study population who do not meet the AKI criteria and are matched 1:1 based on age, sex, year of visit, and baseline renal function.
Who cannot join
- Individuals under 20 years old
- Individuals who did not undergo serum creatinine tests meeting the criteria
- Individuals with pre-existing end-stage kidney disease (ESKD) who have undergone dialysis or kidney transplantation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Seoul National University Hospital
Seoul, 03080
Jin Kyung Kwon, M.D., +82-02-2072-4070, jkk1456@naver.com
About this study
Official title: Analysis for Prognosis and Risk Factors for Acute Kidney Injury: Multi-center Cohort Study
The aim of our study is to analyze the accurate diagnosis and prognosis of acute kidney injury (AKI) based on its severity and to define long-term clinical and socioeconomic outcomes.
Investigators defined the AKI group among adults aged 20 years or older who visited enrolled center and underwent at least two blood tests, including serum creatinine, within an interval of 7 days or less and a control group was matched 1:1 to the AKI group based on age, sex, year of visit, and baseline kidney function, forming the study population. Investigators then collected and analyzed various clinical, laboratory, and hospitalization records including demographic data, anthropometric data, laboratory data, and medical history.
- Conditions
- Acute Kidney Injury
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| AKI group | * Aged 20 years or older who visited hospital * Underwent at least two blood tests, including serum creatinine, within an interval of 7 days or less * AKI was defined based on the KDIGO criteria (an increase in serum creatinine by ≥0.3 mg/dL or ≥1.5 times the baseline). | |
| Control group | Control group was matched 1:1 to the AKI group based on age, sex, year of visit, and baseline kidney function, forming the study population. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Serum Creatinine
Measured: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
Secondary outcomes (4)
Change from Baseline in Urine Protein/Creatinine Ratio
Measured: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
Incidence of Receiving Renal Replacement Therapy
Measured: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
Change from Baseline in Serum Hemogloblin Level
Measured: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
Change from Baseline in Serum Albumin Level
Measured: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Mar 2025
- Study start22 Aug 2022
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- More trials run by Seoul National University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 320,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seoul National University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center
- Responsible party
- Sponsor
- Investigators
- Dong Ki Kim, M.D. Ph.D., Principal investigator, Department of Internal Medicine, Seoul National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06898944
- Sponsor's protocol ID
- H-2208-015-1347
- Status last verified
- Mar 2025
- First submitted
- 20 Mar 2025
- Last updated
- 2 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis for Prognosis and Risk Factors for Acute Kidney Injury: Multi-center Cohort Study
- ClinicalTrials.gov ID
- NCT06898944
- Acronym / sponsor ID
- H-2208-015-1347
- Conditions
- Acute Kidney Injury
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 320,000 participants (estimated)
- Lead sponsor
- Seoul National University HospitalUniversity, hospital or other
- Collaborators
- Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center
- Study start
- 22 Aug 2022 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 27 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of our study is to analyze the accurate diagnosis and prognosis of acute kidney injury (AKI) based on its severity and to define long-term clinical and socioeconomic outcomes.
Investigators defined the AKI group among adults aged 20 years or older who visited enrolled center and underwent at least two blood tests, including serum creatinine, within an interval of 7 days or less and a control group was matched 1:1 to the AKI group based on age, sex, year of visit, and baseline kidney function, forming the study population. Investigators then collected and analyzed various clinical, laboratory, and hospitalization records including demographic data, anthropometric data, laboratory data, and medical history.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AKI group | – | –* Aged 20 years or older who visited hospital * Underwent at least two blood tests, including serum creatinine, within an interval of 7 days or less * AKI was defined based on the KDIGO criteria (an increase in serum creatinine by ≥0.3 mg/dL or ≥1.5 times the baseline). |
| Control group | – | –Control group was matched 1:1 to the AKI group based on age, sex, year of visit, and baseline kidney function, forming the study population. |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults (≥20 years old) who visited Parcitipating Medical Center (Seoul National University Hospital, Bundang Seoul National University Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center) between 2006 and 2021
Key inclusion criteria (3 listed)
- Adults over 20 years old who visited Parcitipating Medical Center (Seoul National University Hospital, Bundang Seoul National University Hospital, SMG-SNU Boramae Medical Center, Keimyung University Dongsan Medical Center) between 2006 and 2021
- The AKI group is defined as individuals meeting the AKI diagnostic criteria of the KDIGO Guideline (an increase in serum creatinine of ≥0.3 mg/dL or ≥1.5 times the baseline level) is enrolled.
- The Control Group is defined as individuals from the study population who do not meet the AKI criteria and are matched 1:1 based on age, sex, year of visit, and baseline renal function.
Key exclusion criteria (3 listed)
- Individuals under 20 years old
- Individuals who did not undergo serum creatinine tests meeting the criteria
- Individuals with pre-existing end-stage kidney disease (ESKD) who have undergone dialysis or kidney transplantation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change from Baseline in Serum Creatinine
Time frame: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
4 secondary outcomes
Change from Baseline in Urine Protein/Creatinine Ratio
Time frame: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
Incidence of Receiving Renal Replacement Therapy
Time frame: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
Change from Baseline in Serum Hemogloblin Level
Time frame: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
Change from Baseline in Serum Albumin Level
Time frame: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2025.
- Individual participant dataSharing planned: Yes
Related trials for Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dong Ki Kim, M.D. Ph.D. principal investigator
Department of Internal Medicine, Seoul National University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Kidney Injury, run by Seoul National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sehoon Park, M.D. Ph.D. (+82-02-2072-4070, mailofsehoon@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Serum Creatinine (time frame: From Index Date(The Date Which Acute Kidney Injury Occured) Through 5 Years After The Index Date). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2025.